


nSTRIDE® Autologous Protein Solution Kit

Once OA Pain Starts, It's Hard to Stop

Intra-Articular Injection for the Treatment of Knee Osteoarthritis

Once OA pain starts it is hard to stop. The nSTRIDE APS Kit is designed to produce a groundbreaking autologous therapy to treat pain and slow the progression of cartilage degradation and destruction in the knee. The nSTRIDE APS Kit is a cell-concentration system designed to concentrate anti-inflammatory cytokines and anabolic growth factors to significantly decrease pain and promote cartilage health.

- Significantly Reduces Pain Associated with Knee OA up to 2 years¹⁻³
- Significantly Improves function in the Knee Joint associated with OA¹⁻³
- Stimulates Cartilage Cell Proliferation^{4**}
- Blocks Cartilage Destruction^{4**}
- Slows Cartilage Degradation^{4**}
- Point-of-Care
- Single Injection



70% Improvement in Knee Pain at 2 years following a Single Injection^{3*}



Legal Manufacturer
Biomet, Inc.
P.O. Box 587
56 E. Bell Drive
Warsaw, Indiana 46581-0587
USA



Authorized Representative
Biomet UK Ltd.
Waterton Industrial Estate
Bridgend, South Wales
CF31 3XA
UK



ZIMMER BIOMET
Your progress. Our promise.™

1. Kon E, Engebretsen L, Peter Verdonk P, Nehrer Sand Filardo G. "Clinical Outcomes of Knee Osteoarthritis Treated with an Autologous Protein Solution. A 1-year Pilot Double-Blinded Randomized Control Trial. American Journal of Sports Medicine, Oct. 2017.
2. Van Drumpt RA, van der Weegen W, King WJ, Toler K, Macenski M. Safety and treatment effectiveness of a single autologous protein solution injection in patients with knee osteoarthritis. BioResearch Access, Vol 5.1, 2016.
3. Kon E, Engebretsen L, Peter Verdonk P, Nehrer S and Filardo G. "Two-year Clinical Outcomes of An Autologous Protein Solution Injection For Knee Osteoarthritis." ICERS 14th World Congress, under review, 2018.
4. Matuska A, O'Shaughnessy KM, King WJ, Woodell-May JE. Autologous solution protects bovine cartilage explants from IL-1 α and TNF α induced cartilage degradation. J Orthop Res 2013;31(12):1929-35.
** Cell culture assays are not necessarily indicative of clinical outcomes.

*As measured by WOMAC pain scores reported by patients continuing follow-up through 2 years (n = 22).

Zimmer Biomet is obliged and committed to ensure compliance with all applicable laws and regulations, including the MedTech / Mecomed / SAMED Codes of Ethical Business Practice and other applicable industry standards. Please find more information on the standards of the mentioned associations on www.eucomed.org, www.mecomed.org and www.samed.org.za. All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet. This material is intended for health care professionals. Distribution to any other recipient is prohibited. Check for country product clearances and reference product specific instructions for use. For product information, including indications, contraindications, warnings, precautions, and potential adverse effects, see the package insert and www.zimmerbiomet.com. Not for distribution in France. ©2017 Zimmer Biomet